HRs for PFS obtained through univariate comparison between patients from the CLL11 trial with MRD ≥10−4, MRD <10−4 but MRD ≥10−5, and MRD <10−5
| PFS from EOT landmark . | Univariate comparison . | HR . | 95% Confidence interval . | P value . | |
|---|---|---|---|---|---|
| Lower . | Upper . | ||||
| MRD by IGHV leader-based NGS | |||||
| <10−4 but ≥10−5 | vs <10−5 | 4.023 | 1.571 | 10.305 | .004 |
| ≥10−4 | vs <10−5 | 9.065 | 3.882 | 21.167 | <.001 |
| ≥10−4 | vs <10−4 but ≥10−5 | 2.253 | 1.149 | 4.418 | .018 |
| PFS from EOT landmark . | Univariate comparison . | HR . | 95% Confidence interval . | P value . | |
|---|---|---|---|---|---|
| Lower . | Upper . | ||||
| MRD by IGHV leader-based NGS | |||||
| <10−4 but ≥10−5 | vs <10−5 | 4.023 | 1.571 | 10.305 | .004 |
| ≥10−4 | vs <10−5 | 9.065 | 3.882 | 21.167 | <.001 |
| ≥10−4 | vs <10−4 but ≥10−5 | 2.253 | 1.149 | 4.418 | .018 |